Articles of the Month
Videos
Allergy Ranks Highest Impact Factor in Allergy
We are thrilled to announce that the 2024 journal Impact Factors stablished by Clarivate has been released, and we are immensely proud to share that Allergy has been recognised with a Impact Factor of 12.6 as the number one journal in our speciality of Allergy and Clinical Immunology. This outstanding achievement is a testament to the entire team's unwavering commitment and hard work.
The success of Allergy is rooted in several key factors:
Full Commitment and Hard Work: The dedication of our editorial and support teams has been instrumental in driving the journal to new heights.
Rapid Decisions for Submissions: Our efficient submission process ensures that authors receive timely and comprehensive feedback.
Extensive and High-Quality Reviews: We maintain rigorous peer review standards to ensure the publication of only the highest quality research.
Timely Publications: Speedy yet thorough processing of manuscripts guarantees that important research reaches the community promptly.
High Numbers of Impressions and Downloads: The significant engagement with our published papers highlights the journal’s influence and reach within the scientific community.
On behalf of the EAACI Executive Committee, it is our pleasure to extend our heartfelt gratitude to the entire Allergy team.
Special thanks to our Editor-in-Chief, Cezmi Akdis, for his visionary leadership, and our Deputy Editors, Ioana Agache and Marek Jutel, for their invaluable contributions. We also recognize the vital roles of our Associate Editors, including Heimo Breiteneder, Thomas Eiwegger, Wytske Fokkens, Emma Guttman-Yassky, David Jackson, Kari Nadeau, Robyn O’Hehir, Liam O’Mahony, Oliver Pfaar, Alexandra Santos, Claudia Traidl-Hoffmann, De Yun Wang, and Luo Zhang, along with the entire editorial board for their expertise and dedication.
In addition, our heartfelt thanks go to our Managing Editor, Laura Alberch; Graphics Editor, Anna Globinska; Social Media Editor, Ruya Kilic Ogulur; Associate Managing Editor, Marisa McGarry; Production Editor, Sathish Asokan Kannan, and Journal’s Publishing Manager, Lisbeth Cranfield.
Together, we have set a new standard of excellence in Allergy and Clinical Immunology, and we look forward to continuing this upward trajectory. Thank you to everyone who has contributed to making #Allergy a leader in our field!
Maria Torres
EAACI President
Articles
Children with eosinophilic esophagitis non-responsive to combination therapy have distinct esophageal transcriptomic and microbiome profile
Hiremath G, Choksi Y, Correa H, et al.Allergy. First published: 12 July 2024
Forecasting daily total pollen concentrations on a global scale
Makra L, Coviello L, Gobbi A, et al.Allergy. First published: 12 July 2024
Alpine altitude climate treatment improves asthma control, irrespective of biologics use
Fieten, K.B., Drijver-Messelink, M.T., Wolters, R., et al.Allergy. First published: 12 July 2024
Allergen-specific B cell responses in oral immunotherapy-induced desensitization, remission, and natural outgrowth in cow's milk allergy
Satitsuksanoa P, van de Veen W, Tan G, et al.Allergy. First published: 11 July 2024
Childhood infections, asthma and allergy trajectories, and chronic rhinosinusitis in middle age: A prospective cohort study across six decades
Perret JL, Idrose NS, Walters EH, et al.Allergy. First published: 10 July 2024
Incidence and risk factors of cutaneous reactions to the first COVID-19 booster vaccine
et al.Allergy. First published: 09 July 2024
Reaction severity and peach threshold amount during oral challenge in nonspecific lipid transfer protein allergy
Pérez-Sánchez, N., Rondón, C., Cañas, J.A., et al.Allergy. First published: 09 July 2024
Anti-rubella IgG serum levels predict risk for SARS-CoV-2 breakthrough infections
Hollstein, M.M., Dierks, S., Schön, M.P., et al.Allergy. First published: 09 July 2024
Person-centred care in allergen immunotherapy in a digital era
Ng, C.L. and Wang, D.Y. Allergy. First published: 09 July 2024
A recent patent in allergy & immunology: Biomarkers on allergen-specific memory B cells to predict allergen immunotherapy outcome
van Zelm, M.C., O'Hehir, R.E. and McKenzie, C.I. Allergy. First published: 09 July 2024
An algorithm for the diagnosis and treatment of Hymenoptera venom allergy, 2024 update
Sturm, G.J. and Arzt-Gradwohl, L. Allergy. First published: 08 July 2024
Human nasal epithelial cells express IL-5Rα but not the co-receptor CSF2RB and do not signal to IL-5
Sohail, A., Cho, L., Hacker, J., et al.Allergy. First published: 07 July 2024
Anaphylaxis and desensitization differently activate and induce IL-8 release by mast cells in a human peanut allergy in vitro model
Tontini, C., Bahri, R., Simpson, A. and Bulfone-Paus, S. Allergy. First published: 07 July 2024
Correspondence to “The impact of indoor pollution on asthma-related outcomes: A systematic review for the EAACI guidelines on environmental science for allergic diseases and asthma”
Dumas, O. and Le Moual, N. Allergy. First published: 07 July 2024
Prevention of allergic airway and gut inflammation in humanized mice by lactobacilli, bifidobacteria, and butyrate
Khatri, R., Weigmann, B., Shahneh, F., et al.Allergy. First published: 07 July 2024
Genomic variants association with selective hypersensitivity reactions to amoxicillin and clavulanic acid
Nuñez, R., Fernandez-Santamaria, R., Salas, M., et al.Allergy. First published: 05 July 2024
Distinct roles of types 1 and 2 interferons in human eosinophil regulation: A multi-omics analysis
Sasaki, H., Miyata, J., Kawashima, Y., et al. Allergy. First published: 03 July 2024
MMP9 and CCL18 associate with chronic urticaria while type I, IV, and VI collagens change with omalizumab treatment
Bartko, E.A., Mellergaard, M., Groen, S.S., et al.Allergy. First published: 02 July 2024
Legends of allergy and immunology: Otto Scheiner
Breiteneder, H. and Wiedermann, U. Allergy. First published: 02 July 2024
Integrated care pathway for occupational pulmonary diseases
van der Valk, J.P.M., den Besten, L.A.A., Hylkema, T.H., et al.Allergy. First published: 28 June 2024
Altered levels of phospholipases C, diacylglycerols, endocannabinoids, and N-acylethanolamines in patients with hereditary angioedema due to FXII mutation
Ferrara AL, Palestra F, Piscitelli F, et al. Allergy. First published: 27 June 2024
Single-cell RNA sequencing of human blood eosinophils reveals plasticity and absence of canonical cell subsets
Rodrigo-Muñoz, J.M., Naharro-González, S., Callejas, S., et al. Allergy. First published: 27 June 2024
Helminth induced monocytosis conveys protection from respiratory syncytial virus infection in mice
Burgess MO, Janas P, Berry K, et al. Allergy. First published: 26 June 2024
To what extent can wildfires in the Mediterranean influence pollen abundance?
Camacho, I., Caeiro, E., Camacho, R., et al. Allergy. First published: 26 June 2024
Establishment of a novel severe asthma canine model: Feasible research platform of respiratory intervention therapies
Chen, D.-F., Su, Z.-Q., Luo, Y.-L., et al. Allergy. First published: 25 June 2024
Evaluation of dupilumab and benralizumab on peripheral airway resistance and reactance
Chan, R., Stewart, K., Kuo, C.R. and Lipworth, B. Allergy. First published: 25 June 2024
Predicting relapse in chronic spontaneous urticaria: A retrospective cohort study evaluating omalizumab withdrawal regimens
Kucharczyk, A., Marczyk, K., Kucharczyk, B., et al. Allergy. First published: 24 June 2024
The impact of high-IgE levels on metabolome and microbiome in experimental allergic enteritis
Zubeldia-Varela E, Blanco-Pérez F, Barker-Tejeda TC, et al. Allergy. First published: 23 June 2024
Indoor and outdoor pollutants—No safe amount of air to breathe in
Agache, I., Jutel, M. and Akdis, C. Allergy. First published: 23 June 2024
Real-world biologics response and super-response in the International Severe Asthma Registry cohort
Denton E, Hew M, Peters MJ, et al. Allergy. First published: 22 June 2024
Global availability and uptake of psychological services for adults, caregivers and children with food allergy
Knibb RC, Herbert LJ, Jones CJ, et al. Allergy. First published: 21 June 2024
Prevalence and risk factors for milk allergy overdiagnosis in the BEEP trial cohort
Allen HI, Wing O, Milkova D, et al. Allergy. First published: 20 June 2024
Network analysis reveals age- and virus-specific circuits in nasal epithelial cells of extremely premature infants
Wisgrill L, Martens A, Kasbauer R, et al. Allergy. First published: 19 June 2024
An algorithm for the management of radiocontrast media hypersensitivity
Brockow, K. Allergy. First published: 18 June 2024
Biomarkers of peanut allergy in children over time
Foong R-X, Du Toit G, van Ree R, et al. Allergy. First published: 18 June 2024
Reply to correspondence: Correspondence to “the impact of indoor pollution on asthma-related outcomes: A systematic review for the EAACI guidelines on environmental science for allergic diseases and asthma”
Canelo-Aybar, C., Nieto-Gutierrez, W., Rodriguez-Tanta, L.Y., et al. Allergy. First published: 16 June 2024
Type 2 inflammation in cystic fibrosis is a predictor of mortality and targeted with CFTR modulator therapy
et al. Allergy. First published: 16 June 2024
Evaluating alopecia areata risk among patients with seasonal and food allergies: A multicenter cohort study
Garate, D., Thang, C.J., Murphy, T.L., et al. Allergy. First published: 16 June 2024
Comprehensive analysis of resilience of human airway epithelial barrier against short-term PM2.5 inorganic dust exposure using in vitro microfluidic chip and ex vivo human airway models
Goksel O, Sipahi MI, Yanasik S, et al. Allergy. First published: 13 June 2024
German asthma net: Nasal polyposis in patients in the severe asthma registry
Bal, C., Stoshikj, S., Milger, K., et al. Allergy. First published: 12 June 2024
Allergic inflammation triggers dyslipidemia via IgG signalling
Fernández-Gallego N, Castillo-González R, Moreno-Serna L, et al. Allergy. First published: 12 June 2024
Discovery of ILC2 extracellular traps and ILC2 ETosis: A novel feature of group 2 innate lymphoid cells
Xu, Y., Zhou, R., Yang, Y., et al. Allergy. First published: 12 June 2024
The stimulation of TH2 cells results in increased IL-5 and IL-13 production via the H4 receptor
Nikolouli E, Mommert S, Dawodu DM, et al. Allergy. First published: 10 June 2024
A high prevalence of hereditary alpha-tryptasemia in pediatric mastocytoma
Madrange, M., Rossignol, J., Devin, C., et al. Allergy. First published: 08 June 2024
Dupilumab efficacy across serum IgE and blood eosinophil levels in chronic rhinosinusitis with nasal polyposis
Bachert, C., Gevaert, P., Lipworth, B., et al. Allergy. First published: 08 June 2024
Target maintenance dose for peanut OIT is 300 mg protein (or less): Pros and cons
Upton, J. and Elizur, A. Allergy. First published: 06 June 2024
Benralizumab reduces blood basophil percentage and activation in vitro without eliciting degranulation
Gil-Martínez, M., Rodrigo-Muñoz, J.M., Lorente-Sorolla, C., et al. Allergy. First published: 06 June 2024
STING/RANTES pathway in airway epithelium enhances Der p1-induced airway inflammation
Tsuji, M., Kondo, M., Nishiyama, A., et al. Allergy. First published: 04 June 2024
Correspondence to “Salivary Immunoinflammatory Proteins Identify Children with Eosinophilic Esophagitis”
Votto, M., Strisciuglio, C., Indolfi, C., et al. Allergy. First published: 04 June 2024
Integrating multi-omics approaches in deciphering atopic dermatitis pathogenesis and future therapeutic directions
Nakajima S, Nakamizo S, Nomura T, et al. Allergy. First published: 04 June 2024
Citations: 342
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
Zuberbier, T, Abdul Latiff, AH, Abuzakouk, M, Aquilina, S, Asero, R, Baker, D, et al. Allergy. 2022; 77: 734– 766
Citations: 147
EAACI guidelines: Anaphylaxis (2021 update)
Muraro A, Worm M, Alviani C, et al. Allergy. 2022; 77: 357–377
Citations: 118
The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update
Maurer M, Magerl M, Betschel S, et al. Allergy. 2022; 77: 1961–1990
Citations: 118
The role of peripheral blood eosinophil counts in COVID-19 patients
Xie, G, Ding, F, Han, L, Yin, D, Lu, H, Zhang, M. Allergy. 2021; 76: 471– 482
Citations: 114
Epithelial barrier hypothesis: Effect of the external exposome on the microbiome and epithelial barriers in allergic disease
Celebi Sozener Z, Ozdel Ozturk B, Cerci P, et al. Allergy. 2022; 77: 1418–1449
Citations: 105
Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice
Santos, A.F., Alpan, O. and Hoffmann, H.-J. Allergy. 2021; 76: 2420-2432
Citations: 92
Allergenic components of the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-mediated complement activation
Klimek, L., Novak, N., Cabanillas, B., et al. Allergy. 2021; 76: 3307-3313
Citations: 90
EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines
Sokolowska, M., Eiwegger, T., Ollert, M., Torres, M.J., Barber, D., Del Giacco, S., et al. Allergy. 2021; 76: 1629-1639
Citations: 88/h5>
The role of allergen-specific IgE, IgG and IgA in allergic disease
Shamji MH, Valenta R, Jardetzky T, et al. Allergy. 2021; 76: 3627–3641
Citations: 82
COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper
Pfaar, O, Klimek, L, Jutel, M, Akdis, C, A, Bousquet, J, Breiteneder, H, et al. Allergy. 2021; 76: 648– 676
Citations: 81
Advances and highlights in allergic rhinitis
Zhang Y, Lan F, Zhang L. Allergy. 2021; 76: 3383–3389
Citations: 79
Allergic reactions to the first COVID-19 vaccine: A potential role of polyethylene glycol?
Cabanillas, B., Akdis, C.A. and Novak, N. Allergy. 2021; 76: 1617-1618
Citations: 76
Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines
Agache, I., Song, Y., Alonso-Coello, P., Vogel, Y., Rocha, C., Solà, I., et al. Allergy. 2021; 76: 2337-2353
Citations: 74
Interleukin-31: The “itchy” cytokine in inflammation and therapy
Datsi, A., Steinhoff, M., Ahmad, F., Alam, M. and Buddenkotte, J. Allergy. 2021; 76: 2982-2997
Citations: 73
Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches
Kato A, Peters AT, Stevens WW, Schleimer RP, Tan BK, Kern RC. Allergy. 2022; 77: 812–826
Citations: 70
Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives
Sampath, V., Rabinowitz, G., Shah, M., et al. Allergy. 2021; 76: 1640-1660
Citations: 69
Advances and highlights in biomarkers of allergic diseases
Ogulur I, Pat Y, Ardicli O, et al. Allergy. 2021; 76: 3659–3686
Citations: 69
Regulatory B cells, A to Z
Jansen, K., Cevhertas, L., Ma, S., Satitsuksanoa, P., Akdis, M. and van de Veen, W.
Citations: 62
Advances and highlights in asthma in 2021
Agache I, Eguiluz-Gracia I, Cojanu C, et al. Allergy. 2021; 76: 3390–3407
Citations: 62
Predictors of treatment response in chronic spontaneous urticaria
Fok, J.S., Kolkhir, P., Church, M.K. and Maurer, M. Allergy. 2021; 76: 2965-2981
Citations: 61
The ingenious mast cell: Contemporary insights into mast cell behavior and function
Dahlin, J.S., Maurer, M., Metcalfe, D.D., Pejler, G., Sagi-Eisenberg, R. and Nilsson, G. Allergy. 2022; 2022; 77: 83-99
February 2023 - Food Allergy and Allergic/Inflammatory Gastrointestinal Diseases
Volume 78 | Issue 2
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
Zuberbier, T, Abdul Latiff, AH, Abuzakouk, M, et al. Allergy. 2022; 77: 734– 766
The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
Zuberbier, T., Aberer, W., Asero, R., Abdul Latiff, A., H., Baker, D., Ballmer-Weber, B. et al. Allergy. 2018; 73: 1393- 1414
Risk factors for severe and critically ill COVID-19 patients: A review
Gao, Y-D, Ding, M, Dong, X, et al. Allergy. 2021; 76: 428– 455
Vaccines and allergic reactions: the past, the current COVID-19 pandemic, and future perspectives
Sampath, V., Rabinowitz, G., Shah, M., Jain, S., Diamant, Z., Jesenak, M. et al. Allergy. 2021; 76: 1640-1660
Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19
Azkur, A.,K., Akdis, M., Azkur, D., Sokolowska, M., van de Veen, W., Brüggen, M.,C. et al. Allergy. 2020; 75: 1564– 1581
EAACI guidelines: Anaphylaxis (2021 update)
Muraro, A, Worm, M, Alviani, C, et al. Allergy. 2022; 77: 357– 377
Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)
Bousquet, J., Khaltaev, N., Cruz, A.A., Denburg, J., Fokkens, W.J., Togias, A. et al. Allergy. 2008; 63: 8-160
Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China
Zhang, J.-J., Dong, X., Cao, Y.-Y., Yuan, Y.-D., Yan, Y.-Q., Akdis, C., A. and Gao, Y.-D. Allergy. 2020; 75: 1730– 1741
Advances and recent developments in asthma in 2020
Cevhertas, L, Ogulur, I, Maurer, DJ, et al. Allergy. 2020; 75: 3124– 3146
The international WAO/EAACI guideline for the management of hereditary angioedema – the 2021 revision and update
Maurer, M., Magerl, M., Betschel, S., et al. Allergy. First published: 10 January 2022
A compendium answering 150 questions on COVID-19 and SARS-CoV-2
Riggioni, C., Comberiati, P., Giovannini, M., Agache, I., Akdis, M., Alves-Correia, M. et al. Allergy. 2020; 75: 2503– 2541
Special Issue: Perspectives in Allergen Immunotherapy: 2019 and Beyond
Volume 74 | Issue S108
Management of anaphylaxis due to COVID-19 vaccines in the elderly
Bousquet, J., Agache, I., Blain, H., et al. Allergy. 2021; 76: 2952-2964
Predictors of treatment response in chronic spontaneous urticaria
Fok, J.S., Kolkhir, P., Church, M.K. and Maurer, M. Allergy. 2021; 76: 2965-2981
Interleukin-31: The “itchy” cytokine in inflammation and therapy
Datsi, A., Steinhoff, M., Ahmad, F., Alam, M. and Buddenkotte, J. Allergy. 2021; 76: 2982-2997
Markers for the involvement of endothelial cells and the coagulation system in chronic urticaria: A systematic review
Mostmans, Y., De Smedt, K., Richert, B., et al. Allergy. 2021; 76: 2998-3016
Eczema herpeticum in atopic dermatitis
Traidl, S., Roesner, L., Zeitvogel, J. and Werfel, T. Allergy. 2021; 76: 3017-3027
CytoBas: Precision component-resolved diagnostics for allergy using flow cytometric staining of basophils with recombinant allergen tetramers
McKenzie, C.I., Varese, N., Aui, P.M., et al. Allergy. 2021; 76: 3028-3040
Heterogeneity of pollen food allergy syndrome in seven Southern European countries: The @IT.2020 multicenter study
Lipp, T, Acar Şahin, A, Aggelidis, X, et al. Allergy. 2021; 76: 3041– 3052
Direct assessment of individual skin barrier components by electrical impedance spectroscopy
Mannweiler, R., Bergmann, S., Vidal-y-Sy, S., Brandner, J.M. and Günzel, D. Allergy. 2021; 76: 3094-3106
Prenatal paraben exposure and atopic dermatitis-related outcomes among children
Thürmann, L, Herberth, G, Seiwert, B, et al. Allergy. 2021; 76: 3122– 3132
Free human DNA attenuates the activity of antimicrobial peptides in atopic dermatitis
Kopfnagel, V, Dreyer, S, Zeitvogel, J, et al. Allergy. 2021; 76: 3145– 3154
Nanoarchitectures for efficient IgE cross-linking on effector cells to study amoxicillin allergy
Tesfaye, A., Rodríguez-Nogales, A., Benedé, S., et al. Allergy. 2021; 76: 3183-3193
Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine
Darrigade, A.-S., Théophile, H., Sanchez-Pena, P., et al. Allergy. 2021; 76: 3194-3196
Transgenic mice overexpressing the PGE2 receptor EP2 on mast cells exhibit a protective phenotype in a model of allergic asthma
Urbano, A., Plaza, J., Turon, S., et al. Allergy. 2021; 76: 3196-3199
Type 2 biomarker expression (FeNO and blood eosinophils) is higher in severe adult-onset than in severe early-onset asthma
Lommatzsch, M., Klein, M., Stoll, P. and Virchow, J.C. Allergy. 2021; 76: 3199-3202
Identification of Ulocladium chartarum as an important indoor allergen source
Pfeiffer, S., Sandler, P., Raith, M., et al. Allergy. 2021; 76: 3202-3206
Effects of allergen immunotherapy in the MASK-air study: a proof-of-concept analysis
Pfaar, O., Sousa-Pinto, B., Devillier, P., et al. Allergy. 2021; 76: 3212-3214
Predicted number of peanut-allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: A novel approach to assessing relevance
Remington, B.C., Koppelman, S.J., Green, T.D., et al. Allergy. 2021; 76: 3223-3226
Legends of allergy and immunology: Sergio Bonini
Maltese, G. and Rasi, G. Allergy. 2021; 76: 3227-3229
Medical algorithm: Peri-operative management of mastocytosis patients
Bocca-Tjeertes, I.F.A., van de Ven, A.A.J.M., Koppelman, G.H., et al. Allergy. 2021; 76: 3233-3235
Open Access Agreements with Wiley
Check here if your research institution has an agreement with Wiley to make your Original Articles and Review Articles free to read, download and share by everyone: Institutional Payments | Wiley
Junior Members Corner
Dear Junior Members,
The EAACI Annual Congress 2024 was held from May 31 to June 3 in the vibrant city of Valencia, Spain. The event was an outstanding success! With an on-site attendance of 8,000 delegates, and more than 140 scientific sessions in which cutting-edge research in the field of Allergy and Clinical Immunology was presented and discussed.
The meeting provided fantastic opportunities for EAACI Junior Members (JMs) to enhance their knowledge in the field and network with other JMs through several activities specifically tailored for junior attendees.
The junior member assembly (JMA) organised a wide variety of scientific symposia, highlighting presentations by our colleagues from the American Academy of Allergy, Asthma & Immunology, Dr. Stella Hartono, and Dr. Heike Hawerkamp from the young European Federation of Immunological Societies. Moreover, JMA organised the year in Review of the 3 EAACI Journals: Allergy, PAI, and CTA, where the outstanding achievements of these journals over the past year were highlighted. We were also able to attend the NAS-JMA and JMA-ROC symposia. Of great importance was the initiatives symposium, where the mentorship and fellowship programmes were presented, as well as the Allergopharma Award, not to mention the traditional JM poster and clinical case sessions.
For first time after the meeting held in Lisbon (2019), the JM event was held in the picturesque gardens of Villa Indiano. Here we celebrated the success of EAACI JMs and networked with our fellow JMs.
It is worth mentioning the important educational initiatives organised by the JMA, such as the JM Quiz, the Allergy College for undergraduate students, including the online session held immediately following the congress, or the 2nd edition of “Tell Us About Your Project”, which covered the expenses, and allowed the participation of JMs in the EAACI meeting. In sort, the JMA would like to thank all the JMs who participated in these events and all EAACI members who made this meeting a total success.
Looking forward to seeing you all again at the next congress in Glasgow!
Best regards,
The Junior Member Assembly
EAACI Patients Organisation Committee Corner
The POC Reunion in the Annual Congress 2023
The POC has been participating in the EAACI Annual Congresses and focused meetings such as FAAM and PAAM since 2011. When Covid-19 pandemic and strict public health measures started in 2020, POC members continued attending the EAACI events virtually. For the first time in a long while, the POC returned to in-person participation in the Annual Congress Hamburg 2023.
Fifteen members of the committee attended the Annual Congress 2023 in-person. The special session ESS1 which was completely organised by the POC took place on the first day of the Congress with great success. Session was designed to discuss the “Benefits of engaging with patients in clinical trials and decision-making” with different stakeholders.
Giulia Gabrielli from European Medicine Agency (EMA) shared the framework for engagement between the Agency and the patients. Dr Kirsten Perrett, Director of Australia National Allergy Centre of Excellence, shared their experience in receiving the federal funding for allergy prevention and management in collaboration with the POC member Allergy & Anaphylaxis Australia. Susanna Palkonen, Director of European Federation of Allergy and Airways Diseases Patients Associations (EFA) presented their long-lasting track record in participation to research projects. POC Member Mikaela Odemyr, President of Asthma and Allergy Association Sweden shared her experience as a patient representative in participating the research design and planning process.
The session chairs were Carla Jones, CEO of Allergy UK, past POC Co-Chair and Ozlem Ceylan, President of Living with Allergy Association, current POC Chair. The session also had a panel discussion where chairs invited the audience to share their experiences and best practises.
Additionally, POC members Sabine Schnadt (DAAB-Germany) presented “Managing the risk of patients with peanut allergy: the value of thresholds of reaction” in the industry session, Patricia Carmelo and Carolina Olivares (Fundacion Creciendo con Alergias Alimenarias-Chile) had two poster presentations; “Food Allergens that trigger anaphylaxis in children in Chile” and “Adrenaline Auto-injector in Chile, National Survey 2020”.
Several POC members attended the Beat Allergy Run & Walk on the 10th of June. The event was organised to contribute on providing much-needed aid as the collected funds were sent to those affected by the earthquakes in Turkey.
The POC believes the conferences and in-person meetings are useful in staying up to date with new developments in medicine, dissemination of knowledge, enabling interaction with opinion leaders, networking, developing consensus, and adoption of newer ideas relevant to the patient community. Going forward, committee members consider hybrid conventions a decent opportunity to increase accessibility and inclusivity. In 2024, POC is planning to attend the Annual Congress in Valencia and FAAM in Athens.
